ISSN:
1619-7089
Keywords:
Key words: Radioimmunoscintigraphy
;
Monoclonal antibody
;
Breast adenocarcinoma
;
Radiation dosimetry
;
Pharmacokinetics
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract. Fifty-three women with clinical evidence of adenocarcinoma of the breast were studied with technetium-99m labelled monoclonal antibody (MAb) 170H.82 at protein doses of 1, 2 and 4 mg. An overall per lesion efficacy of 83.5% sensitivity and 97.7% positive predictive value was obtained. Efficacy appears higher in lesions restricted to the breast and local regional disease than systemic metastases. For the 2 mg dose the breast/local regional disease efficacy was 90% sensitivity and 90.2% positive predictive value. The biodistribution of this MAb was best represented by a two-compartment model with a distribution-phase half-life of 4.0±1.4 h, followed by an elimination-phase half-life of 39.6±6.6 h. In all six patients studied, the crticial organ was the kidney, with a mean radiation absorbed dose of 37±6.9 mGy/GBq. The accuracy of this imaging technique allows the development of diagnostic strategies for the routine use of the compound in patients with breast cancer.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00881809
Permalink
